Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

1322 - Renal cell cancer: clinicopathological profile and survival outcomes from a Tertiary Care Centre in India


19 Dec 2015


Poster presentation 1


Priya Tiwari


Annals of Oncology (2015) 26 (suppl_9): 71-79. 10.1093/annonc/mdv524


P. Tiwari1, L. Kumar2, G. Singh3, A. Seth4

Author affiliations

  • 1 Medical Oncology, B.R. Ambedkar Institute Rotary Cancer Hospital (AIMS), 110029 - New Delhi/IN
  • 2 Institute Rotary Cancer Hospital, AIIMS, 110029 - Delhi/IN
  • 3 Pathology, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 4 Urology, All India Institute of Medical Sciences, New Delhi/IN


Abstract 1322


Incidence of renal cell cancer (RCC) is increasing world over. However, data regarding clinicopathological profile is sparse from Indian subcontinent. This study was done to reflect more light on patient profile as well as survival outcomes of RCC from this country.


Four hundred and twenty three patients were retrospectively analysed from duration of 2004-2013. Data was entered in a predesigned format followed by statistical analysis using SPSS version 20.


Median duration of symptoms was 3 months (0-24). Median age was 52 years (8-87) and male: female ratio was 4:1. Thirty five patients (8.3%) were detected in asymptomatic state. Most common symptom was hematuria followed by flank pain. Triad of hematuria, lump and flank pain was present in in 84 patients (20.2%). Overall 293 (69.3 %) patients presented with non-metastatic disease whereas 130 (30.7%) had upfront metastatic disease. Most common histology was clear cell was present in 302 (71.4%). Five year survival in stage 1 was 92.7%, Stage 2- 72.9%, Stage 3-54.6% and Stage 4- 11.5%. On multivariate analysis, factors found to be predictor of poor survival in metastatic setting were performance status ≥2 (HR: 2.32, 95%CI 1.04- 4.61, p =0.03), upfront metastatic disease (HR: 1.63, 95%CI 1.02-2.57, p = 0.037), ≥2organ site of involvement (HR: 2.7, 95%CI:1.87-3.88, p = 0.01), neutrophilia (HR: 1.66, 95%CI1.12-2.43 p = 0.010), lack of any systemic treatment (HR: 1.94, 95%CI1.37-2.75, p = 0.004).


India still has to see stage migration for RCC as seen in many other countries. Higher male-female ratio, young age, advanced stage of disease and fewer asymptomatic presentation are characteristic of Indian patients of RCC.

Clinical trial identification

not applicable


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings